Christopher Kroeger Sells 118,235 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) CEO Christopher Kroeger sold 118,235 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $27.19, for a total transaction of $3,214,809.65. Following the transaction, the chief executive officer owned 1,394,094 shares of the company’s stock, valued at $37,905,415.86. This trade represents a 7.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maplight Therapeutics Stock Up 2.2%

NASDAQ MPLT opened at $27.08 on Wednesday. Maplight Therapeutics, Inc. has a 52 week low of $12.24 and a 52 week high of $33.28. The firm has a market cap of $1.15 billion and a PE ratio of -0.66. The business’s 50 day moving average price is $24.58.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.43). Sell-side analysts predict that Maplight Therapeutics, Inc. will post -4.36 earnings per share for the current year.

Institutional Trading of Maplight Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Fcpm Iii Services B.V. purchased a new stake in Maplight Therapeutics in the 4th quarter valued at $56,672,000. T. Rowe Price Investment Management Inc. purchased a new stake in Maplight Therapeutics in the 4th quarter valued at $49,154,000. Goldman Sachs Group Inc. purchased a new stake in Maplight Therapeutics in the 4th quarter valued at $34,026,000. Nan Fung Group Holdings Ltd purchased a new stake in Maplight Therapeutics in the 4th quarter valued at $17,060,000. Finally, 5AM Venture Management LLC purchased a new stake in Maplight Therapeutics in the 4th quarter valued at $16,687,000.

Analyst Ratings Changes

Several brokerages have recently issued reports on MPLT. TD Cowen began coverage on shares of Maplight Therapeutics in a report on Tuesday, April 7th. They issued a “buy” rating for the company. Canaccord Genuity Group began coverage on shares of Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 target price for the company. HC Wainwright began coverage on shares of Maplight Therapeutics in a report on Monday, May 4th. They issued a “buy” rating and a $45.00 target price for the company. Weiss Ratings began coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Finally, Needham & Company LLC began coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.43.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.